NO2792369T3 - - Google Patents

Info

Publication number
NO2792369T3
NO2792369T3 NO14177306A NO14177306A NO2792369T3 NO 2792369 T3 NO2792369 T3 NO 2792369T3 NO 14177306 A NO14177306 A NO 14177306A NO 14177306 A NO14177306 A NO 14177306A NO 2792369 T3 NO2792369 T3 NO 2792369T3
Authority
NO
Norway
Application number
NO14177306A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2792369(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2792369T3 publication Critical patent/NO2792369T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO14177306A 2009-02-25 2010-02-24 NO2792369T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20854109P 2009-02-25 2009-02-25
US26994409P 2009-07-01 2009-07-01
US27136409P 2009-07-20 2009-07-20
US27929309P 2009-10-19 2009-10-19
EP10745872.1A EP2400987B1 (en) 2009-02-25 2010-02-24 Bendamustine cyclopolysaccharide compositions

Publications (1)

Publication Number Publication Date
NO2792369T3 true NO2792369T3 (cg-RX-API-DMAC7.html) 2018-09-15

Family

ID=42631521

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14177306A NO2792369T3 (cg-RX-API-DMAC7.html) 2009-02-25 2010-02-24

Country Status (12)

Country Link
US (2) US8436032B2 (cg-RX-API-DMAC7.html)
EP (2) EP2400987B1 (cg-RX-API-DMAC7.html)
JP (1) JP5654498B2 (cg-RX-API-DMAC7.html)
KR (1) KR101798951B1 (cg-RX-API-DMAC7.html)
CN (2) CN102935080A (cg-RX-API-DMAC7.html)
AU (1) AU2010217297A1 (cg-RX-API-DMAC7.html)
CA (1) CA2753641C (cg-RX-API-DMAC7.html)
ES (2) ES2525257T3 (cg-RX-API-DMAC7.html)
HU (1) HUE038234T2 (cg-RX-API-DMAC7.html)
NO (1) NO2792369T3 (cg-RX-API-DMAC7.html)
RU (2) RU2734236C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010097700A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
EP2758052B9 (en) * 2011-09-18 2019-03-27 Euro-Celtique S.A. Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
HRP20230276T1 (hr) 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
ES2972227T3 (es) 2012-03-20 2024-06-11 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
US20150313915A1 (en) * 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
CN109953954A (zh) * 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
AU2018346395A1 (en) * 2017-10-05 2020-04-30 Mecox Curemed Co., Ltd. Oral bendamustine formulations
US11730815B2 (en) * 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
EP3897626B1 (en) 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma
CA3145107A1 (en) * 2020-04-09 2021-10-14 Yue Jing Bendamustine and cyclodextrin composition and use thereof
CN111557904A (zh) * 2020-04-09 2020-08-21 比卡生物科技(广州)有限公司 苯达莫司汀组合物及其用途
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition
WO2026053005A1 (en) * 2024-09-06 2026-03-12 Softkemo Pharma Corp. Stable aqueous bendamustine-cyclodextrin composition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5068226A (en) * 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
DE59607089D1 (de) * 1995-03-10 2001-07-19 Roche Diagnostics Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
US6346274B1 (en) * 1995-03-10 2002-02-12 Roche Diagnostics Gmbh Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof
US6624141B1 (en) * 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
AU2003224099B2 (en) * 2002-04-19 2006-11-09 Novartis Ag Novel biomaterials, their preparation and use
DK1581251T3 (da) * 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
WO2005065435A2 (en) * 2003-12-31 2005-07-21 Cydex, Inc. Et Al. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
CA2569137A1 (en) * 2004-06-07 2005-12-22 Nastech Pharmaceutical Company Inc. Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
CA2574555A1 (en) * 2004-08-03 2006-02-09 Royal College Of Surgeons In Ireland Phenytoin formulations, and uses thereof in wound healing
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Fgf−20の調合物、生成方法および使用
EP1814544A4 (en) * 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
CN101119708B (zh) * 2005-01-14 2014-12-24 赛福伦公司 苯达莫司汀冻干药物组合物
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
DK1848813T3 (da) * 2005-01-28 2013-07-15 Univ Brigham Young Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN1846685A (zh) 2006-01-25 2006-10-18 济南帅华医药科技有限公司 含苯达莫司汀和其增效剂的缓释注射剂
CA2669094A1 (en) 2006-11-08 2008-05-29 Novavax,Inc. Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
US8425459B2 (en) * 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
ES2373867T3 (es) * 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
CN101219113A (zh) 2008-01-28 2008-07-16 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
CN101606934B (zh) * 2009-07-27 2011-09-28 江苏奥赛康药业有限公司 盐酸苯达莫司汀组合物

Also Published As

Publication number Publication date
US20130190372A1 (en) 2013-07-25
US8703964B2 (en) 2014-04-22
JP5654498B2 (ja) 2015-01-14
ES2525257T3 (es) 2014-12-19
RU2734236C2 (ru) 2020-10-13
CN102421451A (zh) 2012-04-18
US8436032B2 (en) 2013-05-07
EP2792369A1 (en) 2014-10-22
EP2400987A4 (en) 2012-08-22
RU2011138844A (ru) 2013-04-10
AU2010217297A1 (en) 2011-10-20
CN102935080A (zh) 2013-02-20
EP2400987A1 (en) 2012-01-04
JP2012519657A (ja) 2012-08-30
CA2753641A1 (en) 2010-09-02
ES2675620T3 (es) 2018-07-11
RU2591804C2 (ru) 2016-07-20
RU2016124871A3 (cg-RX-API-DMAC7.html) 2019-11-11
KR101798951B1 (ko) 2017-11-20
WO2010097700A1 (en) 2010-09-02
CN102421451B (zh) 2013-11-06
US20100216858A1 (en) 2010-08-26
EP2792369B1 (en) 2018-04-18
EP2400987B1 (en) 2014-09-03
CA2753641C (en) 2014-09-16
KR20120015294A (ko) 2012-02-21
RU2016124871A (ru) 2018-12-04
HUE038234T2 (hu) 2018-10-29

Similar Documents

Publication Publication Date Title
BE2015C040I2 (cg-RX-API-DMAC7.html)
BRPI0925311A2 (cg-RX-API-DMAC7.html)
BR112012008195A2 (cg-RX-API-DMAC7.html)
BRPI0924307A2 (cg-RX-API-DMAC7.html)
BR112012012396A2 (cg-RX-API-DMAC7.html)
BR112012000665A2 (cg-RX-API-DMAC7.html)
BR122021004633A2 (cg-RX-API-DMAC7.html)
BR112012003080A2 (cg-RX-API-DMAC7.html)
BR112012012487A2 (cg-RX-API-DMAC7.html)
BRPI0924534A2 (cg-RX-API-DMAC7.html)
BR112012003853A2 (cg-RX-API-DMAC7.html)
BR112012009797A2 (cg-RX-API-DMAC7.html)
BR112012009703A2 (cg-RX-API-DMAC7.html)
RU2016124871A3 (cg-RX-API-DMAC7.html)
BR112012010357A2 (cg-RX-API-DMAC7.html)
BR112012001263A2 (cg-RX-API-DMAC7.html)
BR112012007656A2 (cg-RX-API-DMAC7.html)
BR112012014856A2 (cg-RX-API-DMAC7.html)
BR112012000159A2 (cg-RX-API-DMAC7.html)
BR112012007654A2 (cg-RX-API-DMAC7.html)
BR112012007672A2 (cg-RX-API-DMAC7.html)
BR112012007671A2 (cg-RX-API-DMAC7.html)
BR112012000156A2 (cg-RX-API-DMAC7.html)
BRPI0924617A2 (cg-RX-API-DMAC7.html)
BRPI0925022A2 (cg-RX-API-DMAC7.html)